← Leaderboards
Wayne Tam
Weill Medical Coll Of Cornell Univ
$1,312,328
Attributed
$2,624,656
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $588.4K · FY2015–19$1M$750K$500K$250K$0
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$2,624,656 · 1
By mechanism
R01$2,624,656 · 1
Top collaborators
- Olivier Elemento6 shared
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Jason Mathew Butler$8,950,258
- Darko Barisic$879,454
- Sabine Ehrt$39,683,358
- Olivier Elemento$10,592,678
- Fei Wang$8,043,905
Others in their field
Top investigators on “S Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
S LymphomaLarge Cell Diffuse Non-Hodgkin&AposBiopsyHeterogeneityGenesBaseB-Cell LymphomasB-LymphocytesAdultHematopoietic NeoplasmsBiologyCohortCombination Drug TherapyComputer AnalysisHeavy-Chain ImmunoglobulinsDesignDiagnosisDideoxy Chain Termination Dna SequencingDna MethylationBiological MarkersChemotherapyEpigenetic ProcessExome SequencingHigh Risk
Grant awards (6)
The identification and validation of mechanisms and biomarkers for relapse in diffuse large B-cell lymphoma$445,962
R01 · FY2019 · CA
The identification and validation of mechanisms and biomarkers for relapse in diffuse large B-cell lymphoma$530,098
R01 · FY2018 · CA
The identification and validation of mechanisms and biomarkers for relapse in diffuse large B-cell lymphoma$530,098
R01 · FY2017 · CA
The identification and validation of mechanisms and biomarkers for relapse in diffuse large B-cell lymphoma$530,098
R01 · FY2016 · CA
The identification and validation of mechanisms and biomarkers for relapse in diffuse large B-cell lymphoma (Administrative Supplement)$58,302
R01 · FY2016 · CA
The identification and validation of mechanisms and biomarkers for relapse in diffuse large B-cell lymphoma$530,098
R01 · FY2015 · CA